Legal Amendments, Regulatory Tightening and Legal Violations
First written in FY2016. 3 of 4 entries say "Restated". Latest entry: FY2020.
The whole theme swung hardest in 2025: 6 of 34 companies on the "Worse" side.
75 other companies' latest entry also says "Restated".
- FY2020RestatedAnnual report
「If tighter regulations or the introduction of new regulations constrain business activities and delay individual clinical trial operations, the Group's performance could be affected.」
The risks of business constraints and a loss of confidence resulting from tighter or newly introduced regulations such as the Pharmaceuticals and Medical Devices Act, enforcement regulations and GCP, as well as serious regulatory violations, continue. - FY2018RestatedAnnual report
「If tighter regulations or the introduction of new regulations constrain business activities and delay individual clinical trial operations, the Group's performance could be affected.」
The risks of business constraints and a loss of confidence resulting from tighter or newly introduced regulations such as the Pharmaceuticals and Medical Devices Act, enforcement regulations and GCP, as well as serious regulatory violations, continue. - FY2017RestatedAnnual report
「If tighter regulations or the introduction of new regulations constrain business activities and delay individual clinical trial operations, the Group's performance could be affected.」
The risks of business constraints and a loss of confidence resulting from tighter or newly introduced regulations such as the Pharmaceuticals and Medical Devices Act, enforcement regulations and GCP, as well as serious regulatory violations, continue. - FY2016First statedAnnual report
「If tighter regulations or the introduction of new regulations constrain business activities and delay individual clinical trial operations, the Group's performance could be affected.」
The risks identified include tighter or newly introduced regulations such as the Pharmaceuticals and Medical Devices Act, enforcement regulations and GCP, as well as a loss of confidence resulting from serious regulatory violations.